Brinter® CEO points to transformational potential of 3D bioprinting

news-releasesBrinter Ltd.
November 18th 2022

Turku, Finland: – Brinter®, the developer of pioneering modular multi-material 3D bioprinter platforms, says the technology of bioprinting has the potential to revolutionize drug discovery right across the value chain.

In an interview in the current issue of Drug Discovery World, Brinter® CEO Tomi Kalpio points to the cumbersome nature of conventional drug discovery processes, with successive stages to be tested  across diverse populations from cells to humans, followed by multiple approvals to satisfy various agencies.

Acceleration through human matching 

“It is made as a one-size-fits-all approach based on huge trials. This is where personalized drug screening and personalized treatment come in because we can map the pharmacogenetics, toxicity and drug metabolism of the active pharmaceutical ingredient for the particular individual,” says Kalpio.

He explained that using bioprinted tissue models based on human cells could radically accelerate drug discovery eliminating unsafe drug candidates much earlier, while also eliminating need for animal models in testing.

On demand drug bioprinting

“Furthermore, complex personalized formulations can be 3D printed on demand. This precision printing in 3D requires automation to make it accurate enough,’ noted Kalpio.

He said this aspect of bioprinting also had profound implications for the way clinical trials are structured and supported.

“In essence, manufacturing complex drugs with controlled drug delivery or release profile enhances the therapy that is based on the patient’s individual data,” said Tomi Kalpio.

About Brinter®

Founded in 2020 via partial demerger in Turku, Finland, Brinter® is the manufacturer of a modular multi-material bioprinting platform scalable from manual R&D to automated production. The company works with science and bioengineering organizations to integrate 3D bioprinting into their research, manufacturing, and treatment methods. The goal is to break through current technological limitations and improve people’s quality of life.

Brinter® has bootstrapped its growth since 2019, when it launched its first product, and is currently active in more than ten countries, including USA, Germany, India, and the UK.

Customers of the company now include bio and pharmaceutical companies like Nanoform, as well as research organizations like VTT, BEST group at the University of Glasgow, Johannes Gutenberg University of Mainz, the University of Oulu, and the University of Helsinki, whose directors are enthusiastic about the technology’s potential.

For more information, visit


Click on A personal touch: the role of bioprinting in drug discovery to read the entire interview.
Click on Brinter – Easy to use to see video of Brinter® 1 in action.


Brinter® One - A Modular 3D Bioprinter

Brinter® CEO points to transformational potential of  3D bioprinting

Brinter® CEO Tomi Kalpio (right) with some of the company’s bioprinting platforms.